MetaCap

Cooper Companies (COO) vs RxSight (RXST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cooper Companies (COO) has outperformed RxSight (RXST) over the past year, losing 22.0% versus a loss of 56.0%. Over five years, COO leads with a -38.0% price change compared with -63.9% for RXST. Cooper Companies is the larger company by market cap ($11.20 billion vs $187.4 million), about 59.7 times the size.

Cooper Companies converts more of its revenue into profit, with a net margin of 9.2% versus -29.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COO-21.98%RXST-55.96%
+33%-13%-60%
Nov 21, 20251 yearNov 20, 2026
COO-41.86%RXST-66.94%
+377%+145%-88%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COO versus RXST key metrics
MetricCOORXST
Share price$58.88$4.47
Market cap$11.20B$187.42M
1-day change-2.40%-3.04%
YTD return-28.16%-57.10%
1-year return-21.98%-55.96%
5-year return-38.01%-63.86%
P/E ratio (TTM)20.23—
Forward P/E12.55—
EPS (TTM)$2.91$-1.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.09B$134.48M
Revenue growth (YoY)+5.06%-3.89%
Net income (latest FY)$374.90M$-38.94M
Gross margin65.54%76.60%
Operating margin16.69%-35.84%
Net margin9.16%-28.96%
52-week high$89.83$13.22
52-week low$51.01$4.11
Distance from 52-week high-34.45%-66.19%
Analyst consensusholdhold
Avg. price target upside+11.75%+36.47%
Average volume3.55M826.96K
Shares outstanding190.16M41.93M
Employees15,000461
SectorHealth CareHealth Care
IndustryOphthalmic GoodsOphthalmic Goods

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Cooper Companies is about 59.7 times larger than RxSight by market value ($11.20B vs $187.42M).
  • COO has outperformed RXST by 34.0 percentage points over the past year.
  • Cooper Companies is more profitable, keeping 9.2 cents of every revenue dollar as net income versus -29.0 cents for RxSight.
  • Cooper Companies grew revenue faster in its latest fiscal year (+5.06% vs -3.89%).

About Cooper Companies

COO stock →

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical.

Health Care · Ophthalmic Goods · 15,000 employees

About RxSight

RXST stock →

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Health Care · Ophthalmic Goods · 461 employees

COO vs RXST FAQ

Which is bigger, Cooper Companies or RxSight?

Cooper Companies (COO) is larger, with a market capitalization of $11.20B compared with $187.42M for RxSight (RXST).

Which stock has performed better over the past year, COO or RXST?

COO returned -21.98% over the past 12 months, compared with -55.96% for RXST (price return, excluding dividends). Past performance does not predict future results.

Are Cooper Companies and RxSight in the same industry?

Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.

More comparisons